STAR

Strides Pharma Science Share Price

 

 

Start SIP in STAR

Start SIP

Performance

  • Low
  • ₹878
  • High
  • ₹918
  • 52 Week Low
  • ₹513
  • 52 Week High
  • ₹1,025
  • Open Price₹906
  • Previous Close₹900
  • Volume263,462

Investment Returns

  • Over 1 Month + 3.75%
  • Over 3 Month + 11.06%
  • Over 6 Month + 1.3%
  • Over 1 Year + 38.21%

Smart Investing Starts Here Start SIP with Strides Pharma Science for Steady Growth!

Invest Now

Strides Pharma Science Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 21.1
  • PEG Ratio
  • 0.3
  • Market Cap Cr
  • 8,400
  • P/B Ratio
  • 3
  • Average True Range
  • 30.93
  • EPS
  • 47.3
  • Dividend Yield
  • 0.4
  • MACD Signal
  • 4.85
  • RSI
  • 51.56
  • MFI
  • 70.86

Strides Pharma Science Financials

Strides Pharma Science Technicals

EMA & SMA

Current Price
₹911.35
+ 11 (1.22%)
pointer
  • Bearish Moving Average 1
  • Bullish Moving Average 15
  • 20 Day
  • ₹907.12
  • 50 Day
  • ₹896.88
  • 100 Day
  • ₹879.46
  • 200 Day
  • ₹865.55

Resistance and Support

902.47 Pivot Speed
  • R3 966.83
  • R2 942.42
  • R1 926.88
  • S1 886.93
  • S2 862.52
  • S3 846.98

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Strides Pharma Science Ltd. is a global pharmaceutical company engaged in the development, manufacturing, and marketing of generic drugs. It focuses on niche therapeutic segments, including anti-retrovirals, oncology, and central nervous system, serving markets worldwide.

Strides Pharma Science has an operating revenue of Rs. 4,684.63 Cr. on a trailing 12-month basis. An annual revenue growth of 13% is good, Pre-tax margin of 11% is healthy, ROE of 140% is exceptional. The company has a reasonable debt to equity of 22%, which signals a healthy balance sheet. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 10% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 53 which is a POOR score indicating inconsistency in earnings, a RS Rating of 82 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 60 indicates it belongs to a fair industry group of Medical-Generic Drugs and a Master Score of B is close to being the best. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Strides Pharma Science Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-10-31 Quarterly Results
2025-07-29 Quarterly Results
2025-05-22 Audited Results & Final Dividend
2025-01-30 Quarterly Results
2024-10-24 Quarterly Results
Date Purpose Remarks
2025-07-22 FINAL Rs.4.00 per share(40%)Final Dividend
2024-09-09 FINAL Rs.2.50 per share(25%)Final Dividend
2023-08-04 FINAL Rs.1.50 per share(15%)Final Dividend
2021-08-06 FINAL Rs.2.50 per share(25%)Final Dividend
View Strides Pharma Science Dividend History Arrow

Strides Pharma Science F&O

Strides Pharma Science Shareholding Pattern

27.86%
8.48%
2.94%
28.51%
0.01%
22.43%
9.77%

About Strides Pharma Science

  • NSE Symbol
  • STAR
  • BSE Symbol
  • 532531
  • Managing Director & Group CEO
  • Mr. Badree Komandur
  • ISIN
  • INE939A01011

Similar Stocks to Strides Pharma Science

Strides Pharma Science FAQs

Strides Pharma Science share price is ₹911 As on 02 January, 2026 | 04:36

The Market Cap of Strides Pharma Science is ₹8400.2 Cr As on 02 January, 2026 | 04:36

The P/E ratio of Strides Pharma Science is 21.1 As on 02 January, 2026 | 04:36

The PB ratio of Strides Pharma Science is 3 As on 02 January, 2026 | 04:36

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23